Glucophage® XR – Extended Release

Original metformin

Glucophage® XR is a once-daily extended-release tablet designed to release metformin more slowly and gradually. This formulation is taken only once daily and preferably with an evening meal.

Summary report on drug properties GXR500

Summary report on drug properties GXR750

Summary report on drug properties GXR1000

INDICATIONS

Reduce the risk or delay of manifestation of type 2 diabetes mellitus in adult, obese pre-diabetic patients (IGT and / or IFG, and / or elevated HbA1C *):

Those at high risk for developing type 2 diabetes mellitus and
Where despite the intense lifestyle changes applied from 3 to 6 months, there is still progression to type 2 diabetes mellitus

The treatment with Glucophage XR must be based on a risk assessment, which includes appropriate glycemic control measures and evidence of high cardiovascular risk. Lifestyle changes should continue after metformin treatment is initiated unless the patient is unable to continue for medical reasons.

*IGT = Imapired Glucose Tolerance

*IFG = Impaired Fasting Glucose

Treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. Glucophage SR may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.